Browse Category

Pharmaceuticals 12 January 2026 - 14 January 2026

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK shares rose in early London trade on Wednesday after Summit Therapeutics said it struck a clinical trial collaboration with the British drugmaker to test a new cancer combination.

14 January 2026

LSE:GSK·NASDAQ:SMMT·Pharmaceuticals·Stock Market

Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly and Company shares were down 0.4% at $1,077.19 in after-hours trading on Tuesday. The U.S. Food and Drug Administration asked drugmakers to remove suicide-related warnings from labels of GLP-1 weight-loss drugs — medicines that mimic a gut hormone to curb appetite — including Lilly’s Zepbound.

14 January 2026

NYSE:LLY·Pharmaceuticals·Stock Market

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

Kiniksa Pharmaceuticals International, plc saw its shares drop 6.1% to $38.61 on Tuesday, following the release of updated revenue forecasts for its key drug ARCALYST. The stock briefly dipped to an intraday low of $38.27. Yahoo Finance

13 January 2026

Biotechnology·Earnings Reports·NASDAQ:KNSA·Pharmaceuticals·Stock Market

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as a “major amendment” but didn’t request additional safety or manufacturing data. LGND shares opened at $196.96 and fluctuated between $175.89 and $206.78.

13 January 2026

NASDAQ:LGND·NASDAQ:TVTX·Pharmaceuticals·Stock Market

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Shares of Travere Therapeutics dropped 19% to $27.56 in early afternoon trading Tuesday after the U.S. Food and Drug Administration extended its review of the kidney drug Filspari for broader use. The stock had fallen as much as 34% earlier, hitting a low of $22.35.

13 January 2026

NASDAQ:TVTX·Pharmaceuticals·Stock Market

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Shares of Structure Therapeutics climbed roughly 14% on Tuesday, adding to the stock’s recent swings. The move came as investors took a fresh look at the company’s newly announced patent licensing deal with Roche’s Genentech.

13 January 2026

Biotechnology·NASDAQ:GPCR·Pharmaceuticals·Stock Market·SWX:ROG

Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson shares climbed roughly 1.6% to $212.98 on Tuesday, bucking a minor slide in healthcare stocks as the overall market showed little direction. The stock hit a session peak of $213.48 and dipped to $208.93 at its low. Meanwhile, the Health Care Select Sector SPDR ETF fell around 0.3%, with the S&P 500 ETF holding steady.

13 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceuticals·Stock Market

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration's request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo Nordisk’s Wegovy.

13 January 2026

Healthcare Innovation·NYSE:LLY·Pharmaceuticals·Stock Market

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer Inc shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029.

13 January 2026

NASDAQ:VKTX·NYSE:NVO·NYSE:PFE·Pfizer·Pharmaceuticals

Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck & Co boosted its long-term revenue forecast for several new products and pipeline candidates, projecting $70 billion from these “new growth drivers” by the mid-2030s. The company raised its cardiometabolic and respiratory sales outlook to around $20 billion, up from $15 billion, while its infectious-disease forecast jumped to about $15 billion from $5 billion. Merck shares slipped 1.2% to close at $109.19 on Monday. Meanwhile, Johnson & Johnson climbed 2.6%, Eli Lilly added 1.6%, and Pfizer dropped 0.8%.

13 January 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer Inc. shares fell on Monday after Chief Executive Albert Bourla said the cash-pay market for obesity drugs — where patients pay out of pocket — now works “almost like Viagra”, the erectile-dysfunction drug Pfizer launched in 1998. The company, which bought obesity developer Metsera in a deal valued at up to $10 billion and has said it does not expect to return to revenue growth until 2029, closed down 0.8% at $25.27.

13 January 2026

NYSE:NVO·NYSE:PFE·Pharmaceuticals·Stock Market

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam Pharmaceuticals’ shares fell sharply on Monday after the drugmaker’s preliminary fourth-quarter sales for its flagship heart drug Amvuttra came in below Wall Street expectations.

13 January 2026

Earnings Reports·NASDAQ:ALNY·Pharmaceuticals·Stock Market

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

AbbVie shares barely moved in after-hours Monday following a new three-year pricing pact with the Trump administration. The drugmaker also announced two deals to strengthen its pipeline and boost U.S. manufacturing. The stock slipped less than 0.1% to $220.04.

13 January 2026

NYSE:ABBV·Pharmaceuticals·Stock Market

Eli Lilly stock moves after-hours on fast-track weight-loss pill talk and Nvidia AI lab deal

Eli Lilly stock rose about 1.6% in after-hours trading on Monday, last at $1,081, after a top research executive said the drugmaker expects to have enough supply to launch its experimental weight-loss pill orforglipron in “many, many countries” as it nears a U.S. regulatory decision.

13 January 2026

NASDAQ:NVDA·NYSE:LLY·Pharmaceuticals·Stock Market

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam Pharmaceuticals shares dropped in late Monday trading after the RNA interference drugmaker unveiled a new five-year plan and provided early 2026 sales guidance, along with preliminary figures for 2025. The stock slipped roughly 6.7% to $370.91.

12 January 2026

Earnings Reports·NASDAQ:ALNY·Pharmaceuticals·Stock Market

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading.

12 January 2026

NASDAQ:ARQT·Pharmaceuticals·Stock Market

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck & Co shares slipped $1.26, or 1.1%, to $109.27 in Monday afternoon trading. The stock has fluctuated between $111.45 and $108.95 today.

12 January 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Shares of Johnson & Johnson climbed roughly 2.3% to $209.03 on Monday, pushing the stock near the high end of its trading range after new oncology data came out over the weekend.

12 January 2026

Biotechnology·Earnings Reports·NYSE:JNJ·Pharmaceuticals

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie Inc shares slipped Monday following news of a new collaboration with China’s RemeGen to co-develop an experimental solid-tumor drug, as the company ramps up efforts to expand its cancer portfolio via licensing deals. By 1:30 p.m. EST, AbbVie was down 0.6% at $218.81.

12 January 2026

NYSE:ABBV·NYSE:WST·Pharmaceuticals·Stock Market

Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Shares of Recursion Pharmaceuticals climbed Monday following the release of an updated investor presentation via a Form 8-K filing. The Nasdaq-traded stock gained 4.4%, reaching $4.87 late morning, putting the company's market cap near $2.1 billion.

12 January 2026

NASDAQ:RXRX·Pharmaceuticals·Stock Market

Previous 1 … 21 22 23 24 25 … 47 Next

Pharmaceuticals 12 January 2026 - 14 January 2026

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

Eli Lilly stock moves after-hours on fast-track weight-loss pill talk and Nvidia AI lab deal

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

TechStock² Updates

Ondas stock (ONDS) steady with $406 million H2 revenue milestone ahead

Archer Stock (ACHR) Drops 8% with Boeing Agreement Adding Revenue and Causing Dilution

Humana stock (HUM) climbs 3% as 2027 COLA calculations obscure rising medical-cost shortfall

Marex stock (MRX) surges 13% on trading income fueling 98% revenue growth

SpaceX stock (SPCX) climbs 4% as $74 billion advance surpasses Cursor price

Top Stock Picks

AerCap

Uber

Taiwan Semiconductor

AIG

Ferguson

Live updates

Investment Disclaimer